Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Decoding the GLP-1 weight-loss plateau

Decoding the GLP-1 weight-loss plateau

New Capabilities

NIH and others probe why Ozempic and Wegovy stall, and how to push past it

Today: NIH ties semaglutide effect to cAMP signaling

Overview

Patients on Ozempic and Wegovy typically lose about 15% of their body weight, then stall around 14 months in. On May 25, NIH researchers in Nature Metabolism reported what may be happening inside the brain to cause that stall, and a way to keep the drug working longer.

The team watched individual appetite-controlling neurons in the hindbrain's area postrema. Semaglutide hits those cells with wildly varying force, and only the cells that hold a sustained surge of a signaling molecule called cyclic AMP keep suppressing appetite. Block the enzyme that breaks cyclic AMP down using roflumilast, a 2011-approved lung drug, and the response lasts longer in mice.

Why it matters

If the mouse finding holds in people, a drug already on pharmacy shelves could push millions of GLP-1 users past their weight-loss ceiling.

Play on this story Voices Debate Predict Higher or Lower

Key Indicators

~15%
Average weight loss on Wegovy at 68 weeks
Mean body-weight reduction in the STEP 1 trial that supported Wegovy's 2021 approval.
14 months
Typical plateau onset
Approximate point at which weight loss stalls for most semaglutide patients in long-term trials.
2011
Roflumilast FDA approval year
The PDE4 inhibitor has 15 years of human safety data and is sold generically.
Mice
Stage of evidence
The combination effect has been shown in mouse neurons and behavior, not yet in people.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

Play

Exploring all sides of a story is often best achieved with Play.

Log in to play. Track your picks, climb the leaderboards. Log in Sign Up
Predict 4 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play
Higher or Lower Two numbers from this story. Guess which is bigger. 5 rounds to set a streak. Log in to play
Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

Organizations Involved

National Institute of Diabetes and Digestive and Kidney Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
Federal research agency
Lead institution on the May 2026 Nature Metabolism study

One of 27 institutes inside the National Institutes of Health, focused on diabetes, obesity, and kidney disease.
Novo Nordisk
Novo Nordisk
Pharmaceutical company
Maker of semaglutide; primary commercial stakeholder

Danish pharmaceutical company that developed semaglutide and sells it as Ozempic and Wegovy.
Eli Lilly and Company
Eli Lilly and Company
Pharmaceutical company
Maker of tirzepatide; chief GLP-1 competitor

American pharmaceutical company that markets tirzepatide as Mounjaro and Zepbound.

Timeline

April 2005 May 2026

9 events Latest: Today
Tap a bar to jump to that date

  1. NIH ties semaglutide effect to cAMP signaling

    Today Research

    Nature Metabolism paper from NIDDK links the lasting weight-loss effect to sustained cAMP and flags roflumilast as a combination drug.

  2. Wegovy label expanded to cardiovascular protection

    Regulatory

    FDA expands Wegovy label to reduce major cardiovascular events, broadening insurance coverage.

  3. Zepbound launches in weight management

    Regulatory

    FDA approves tirzepatide as Zepbound, putting Lilly in direct competition with Wegovy.

  4. Tirzepatide arrives as Mounjaro

    Regulatory

    FDA approves Eli Lilly's dual GLP-1/GIP agonist for type 2 diabetes; analysts flag larger weight-loss effect.

  5. Wegovy approved for weight management

    Regulatory

    FDA approves semaglutide at 2.4 mg weekly for chronic weight management; cultural takeoff follows.

  6. Ozempic enters the diabetes market

    Regulatory

    FDA approves Novo Nordisk's semaglutide as Ozempic for type 2 diabetes.

  7. First GLP-1 cleared for weight loss

    Regulatory

    FDA approves liraglutide as Saxenda for chronic weight management, validating the obesity indication.

  8. FDA approves roflumilast for COPD

    Regulatory

    Daliresp, a PDE4 inhibitor, is cleared for severe chronic obstructive pulmonary disease.

  9. First GLP-1 drug reaches the U.S. market

    Regulatory

    FDA approves exenatide (Byetta) for type 2 diabetes, opening the GLP-1 receptor agonist class.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

1992-1997

Fen-phen withdrawal (1992-1997)

American Home Products' fenfluramine and dexfenfluramine, paired off-label with phentermine as 'fen-phen', were prescribed to about 6 million Americans for weight loss in the 1990s. In July 1997, Mayo Clinic researchers reported 24 cases of valvular heart disease in fen-phen users. The FDA pulled both fenfluramine drugs that September.

Then

Sales of fenfluramine and dexfenfluramine collapsed within weeks of the Mayo report. American Home Products and its successor Wyeth paid more than $20 billion in settlements over the next two decades.

Now

The FDA imposed cardiovascular outcomes trials on later obesity drugs, which shrank and slowed the field until GLP-1 receptor agonists arrived in the 2010s.

Why this matters now

The most direct prior case of a combination weight-loss therapy that worked but failed on safety. It is why any GLP-1 plus PDE4 candidate will face heavy cardiovascular scrutiny long before launch.

July 1996

HAART for HIV (1996)

Through the early 1990s, single antiretrovirals like AZT extended HIV patients' lives by months before the virus mutated past them. At the 1996 International AIDS Conference in Vancouver, David Ho and others presented data on combining three drugs from different classes. The cocktail drove HIV viral loads to undetectable levels in many patients.

Then

AIDS deaths in the United States fell by about 47% in 1997, the first full year of widespread HAART use.

Now

Combination therapy became the default model in HIV care and a template for tuberculosis, cancer, and hepatitis C. It set the expectation that single drugs hit ceilings and combinations can break through them.

Why this matters now

The clearest precedent for combination therapy breaking a single-drug plateau. The NIH paper proposes a version of the same playbook for obesity, three decades after HAART proved the concept.

Sources

(3)
National Institutes of Health ScienceDaily MedicalXpress